全文获取类型
收费全文 | 74920篇 |
免费 | 7187篇 |
国内免费 | 2255篇 |
专业分类
耳鼻咽喉 | 173篇 |
儿科学 | 763篇 |
妇产科学 | 419篇 |
基础医学 | 2929篇 |
口腔科学 | 574篇 |
临床医学 | 6439篇 |
内科学 | 9048篇 |
皮肤病学 | 1171篇 |
神经病学 | 3030篇 |
特种医学 | 703篇 |
外国民族医学 | 7篇 |
外科学 | 2144篇 |
综合类 | 10003篇 |
一般理论 | 7篇 |
预防医学 | 5576篇 |
眼科学 | 864篇 |
药学 | 33223篇 |
32篇 | |
中国医学 | 3419篇 |
肿瘤学 | 3838篇 |
出版年
2023年 | 1252篇 |
2022年 | 1454篇 |
2021年 | 2410篇 |
2020年 | 2799篇 |
2019年 | 2942篇 |
2018年 | 2864篇 |
2017年 | 3147篇 |
2016年 | 2779篇 |
2015年 | 2734篇 |
2014年 | 4960篇 |
2013年 | 8918篇 |
2012年 | 4882篇 |
2011年 | 5047篇 |
2010年 | 4103篇 |
2009年 | 3607篇 |
2008年 | 3395篇 |
2007年 | 3483篇 |
2006年 | 3114篇 |
2005年 | 2789篇 |
2004年 | 2326篇 |
2003年 | 2120篇 |
2002年 | 1674篇 |
2001年 | 1620篇 |
2000年 | 1272篇 |
1999年 | 1068篇 |
1998年 | 874篇 |
1997年 | 810篇 |
1996年 | 665篇 |
1995年 | 640篇 |
1994年 | 555篇 |
1993年 | 478篇 |
1992年 | 532篇 |
1991年 | 453篇 |
1990年 | 350篇 |
1989年 | 291篇 |
1988年 | 280篇 |
1987年 | 263篇 |
1986年 | 212篇 |
1985年 | 232篇 |
1984年 | 177篇 |
1983年 | 134篇 |
1982年 | 115篇 |
1981年 | 95篇 |
1980年 | 64篇 |
1979年 | 58篇 |
1978年 | 71篇 |
1977年 | 48篇 |
1976年 | 53篇 |
1975年 | 49篇 |
1974年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Tyler B. Kratzer MPH Ahmedin Jemal DVM PhD Kimberly D. Miller MPH Sarah Nash PhD Charles Wiggins PhD Diana Redwood PhD Robert Smith PhD Rebecca L. Siegel MPH 《CA: a cancer journal for clinicians》2023,73(2):120-146
American Indian and Alaska Native (AIAN) individuals are diverse culturally and geographically but share a high prevalence of chronic illness, largely because of obstacles to high-quality health care. The authors comprehensively examined cancer incidence and mortality among non-Hispanic AIAN individuals, compared with non-Hispanic White individuals for context, using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Overall cancer rates among AIAN individuals were 2% higher than among White individuals for incidence (2014 through 2018, confined to Purchased/Referred Care Delivery Area counties to reduce racial misclassification) but 18% higher for mortality (2015 through 2019). However, disparities varied widely by cancer type and geographic region. For example, breast and prostate cancer mortality rates are 8% and 31% higher, respectively, in AIAN individuals than in White individuals despite lower incidence and the availability of early detection tests for these cancers. The burden among AIAN individuals is highest for infection-related cancers (liver, stomach, and cervix), for kidney cancer, and for colorectal cancer among indigenous Alaskans (91.3 vs. 35.5 cases per 100,000 for White Alaskans), who have the highest rates in the world. Steep increases for early onset colorectal cancer, from 18.8 cases per 100,000 Native Alaskans aged 20–49 years during 1998 through 2002 to 34.8 cases per 100,000 during 2014 through 2018, exacerbated this disparity. Death rates for infection-related cancers (liver, stomach, and cervix), as well as kidney cancer, were approximately two-fold higher among AIAN individuals compared with White individuals. These findings highlight the need for more effective strategies to reduce the prevalence of chronic oncogenic infections and improve access to high-quality cancer screening and treatment for AIAN individuals. Mitigating the disparate burden will require expanded financial support of tribal health care as well as increased collaboration and engagement with this marginalized population. 相似文献
2.
肾脏是人体最重要的排泄器官。肾单元近端小管细胞具有多种药物转运体和代谢酶,在药物及其代谢物处置中发挥关键作用。近端小管细胞中主要转运体包括有机阴离子转运体、有机阳离子转运体、有机阳离子/肉毒碱转运体、多药及毒素外排转运蛋白、P-糖蛋白、乳腺癌耐药蛋白和多药耐药相关蛋白;主要代谢酶包括细胞色素P450酶,UDP-葡萄糖醛酸基转移酶、磺酸基转移酶、谷胱甘肽S-转移酶。肾脏转运体和/或代谢酶介导药物相互作用(DDIs)是临床关注的重要问题。肾脏转运体和代谢酶存在密切协作关系,在肾脏也存在多种相互作用现象(包括转运-转运相互作用,代谢-代谢相互作用和转运-代谢相互作用),其显著影响药物肾脏处置、临床疗效和肾毒性。本文系统阐述了这些相互作用对药物及其代谢物的肾脏排泄、药动学、DDIs和肾毒性的影响。今后需要进一步阐明肾脏转运-代谢相互作用机制,将有助于研究体内药物肾脏处置和DDIs,促进临床合理用药。 相似文献
3.
4.
5.
6.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
7.
目的 通过对耐甲氧西林金黄色葡萄球菌(MRSA)、耐碳青霉烯类铜绿假单胞菌(CRPA)、耐碳青霉烯类鲍曼不动杆菌(CRAB)、耐第三代头孢菌素的大肠埃希菌(3GCR-E.coli)、耐第三代头孢菌素的肺炎克雷伯菌(3GCR-KP)等细菌耐药数据构建灰色预测模型,分析细菌耐药特征的变化趋势,探讨灰色预测模型在细菌耐药领域的应用价值。方法 采用2014-2018年全国细菌耐药监测报告中MRSA、CRPA和CRAB、3GCR-E.coli、3GCR-KP等耐药率数据构建灰色预测GM (1,1)模型。用后验差比C值和小误差概率P值评估模型精度,用相对误差和级比偏差评估模型拟合效果,并用2019-2020年数据对模型预测效果进行验证。最终根据模型对2021-2023年的耐药率进行预测。结果 本研究构建的GM (1,1)模型对MRSA、CRPA、CRAB、3GCR-E.coli和3GCR-KP等细菌耐药率预测效果较好,根据该模型预测到2023年其耐药率分别可降低至23.9%、15.2%、50.2%、43.8%、26.1%。结论 全国针对细菌耐药情况采取的控制措施取得明显成效,GM (1,1)模型对细菌耐药率预测效果较好,可在细菌耐药管理领域推广应用。 相似文献
8.
9.
10.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献